Trial Watch: Radioimmunotherapy for oncological indications.
about
Modern Radiotherapy Concepts and the Impact of Radiation on Immune ActivationTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTrial watch: Dendritic cell-based anticancer therapyTrial Watch-Oncolytic viruses and cancer therapyTrial Watch-Immunostimulation with cytokines in cancer therapyTrial Watch: Peptide-based anticancer vaccines.Novel immune checkpoint blocker approved for the treatment of advanced melanomaCombinatorial strategies for the induction of immunogenic cell death.First oncolytic virus approved for melanoma immunotherapy.Doubling the blockade for melanoma immunotherapyThe oncolytic peptide LTX-315 triggers necrotic cell death.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update.Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.Abscopal Effects: Case Report and Emerging Opportunities.The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermiaA Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells.
P2860
Q26744490-B331903C-D7BF-44B9-A7A5-4536D0B8A02CQ26996518-40406822-5BE6-4032-B86B-9117721AC99BQ27004011-16B3D55C-B5AF-43A2-9E23-649F775A95B7Q27024047-7FB7D65C-7A66-46CD-B6D7-C128971329CEQ28072347-4F2A81FF-6339-448E-A15C-9EFB72BA7098Q28078725-6CE321FC-5162-4202-B3AB-B7E8DF7C6FCCQ34483345-4FD5D770-8DDE-42A7-9FBD-28F3A1161A5DQ34936394-89CB3085-EED7-471E-8FF1-0C839CF515CCQ35535140-4A808A09-2F5F-4275-A366-D595CE0A539EQ36597333-9BF6B977-133E-403A-8D60-D044B553D773Q36597356-C0F7F766-E4B6-4B81-A1DC-6258DBDAF837Q36780793-E40182C7-CC07-413E-A264-36822D685207Q37079141-0C753830-B40C-41FD-B069-8909F82DB4EBQ37308207-0BEF2E79-6AE6-4448-82C5-3DCB98836837Q37687496-2F6016A8-15E0-45D4-AF77-5A1B394457CCQ38844399-7A393E1C-6E13-43BF-81C8-BB792E34334AQ41592435-D1F94D3A-B601-48C8-92CE-74647E78BE29Q42222358-5FE85CB6-B219-4CEB-8721-3E83806DDFA0Q42427640-07023E3A-0854-4D49-9C85-A54E5E182D1DQ52680663-3A9C508B-F131-4078-974B-A75CE7354622
P2860
Trial Watch: Radioimmunotherapy for oncological indications.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Trial Watch: Radioimmunotherapy for oncological indications.
@en
Trial Watch: Radioimmunotherapy for oncological indications.
@nl
type
label
Trial Watch: Radioimmunotherapy for oncological indications.
@en
Trial Watch: Radioimmunotherapy for oncological indications.
@nl
prefLabel
Trial Watch: Radioimmunotherapy for oncological indications.
@en
Trial Watch: Radioimmunotherapy for oncological indications.
@nl
P2093
P2860
P50
P1433
P1476
Trial Watch: Radioimmunotherapy for oncological indications.
@en
P2093
Alexander Eggermont
Gwenola Manic
Ilio Vitale
Norma Bloy
P2860
P304
P356
10.4161/21624011.2014.954929
P50
P577
2014-10-01T00:00:00Z